Clinical trial
A PHASE Ib/IIa STUDY OF COMBINATION THERAPY WITH GEMCITABINE AND ATU027 IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA
NCT01808638 is registered in ClinicalTrials.gov with Silence Therapeutics GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A PHASE Ib/IIa STUDY OF COMBINATION THERAPY WITH GEMCITABINE AND ATU027 IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA
- Lead sponsor
- Silence Therapeutics GmbH
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- March 31, 2013
- Completion date
- January 31, 2016
- Enrollment
- 29 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.